Fig. 8. Intravitreal BMS 493 injection improves visual processing in contralateral V1.
(A) Experimental timeline for BMS 493 experiments. P28 rd10 mice were given a bilateral cranial window and allowed to recover for 14 days before treatment. At P43 to P45, vehicle or BMS 493 was injected into separate eyes. Mice were imaged 4 to 6 days after treatment at P49. This allowed comparison of drug effects on retinal-driven cortical responses within the same mouse. (B) Aligned and averaged cross-validated tuning curves across neurons in each treatment condition. Preferred orientation is determined using odd trials, and averaged responses are shown for even trials. Injection of BMS 493 results in increased response amplitude at the preferred orientation compared to vehicle. (C) Neurons contralateral to the BMS 493–treated eye show increased OSI as compared to neurons contralateral to the vehicle eye. Values are shown as means ± SEM. Control: n = 1428 neurons across 13 mice; BMS 493: n = 1577 neurons across 13 mice. F(1,1076) = 10.67, **P = 0.001; two-tailed F test. (D) Neurons contralateral to the BMS 493–treated eye show significantly higher average reliability compared to neurons contralateral to the vehicle treated eye. Control: n = 1429 neurons across 13 mice; BMS 493: n = 1599 neurons across 13 mice. F(1,1961) = 102.51, ***P = 1.61 × 10−23; two-tailed F test. (E) Comparison of reliability segmented by deciles. Reliability is similar in lower deciles but becomes significantly greater for BMS 493 neurons at higher deciles. F(1,1959) = 191.58, ***P = 1.23 × 10−41; two-tailed F test. (F) Performance of a population-level decoder across vehicle (left) and BMS 493–treated (right) populations. (G) Across population sizes, BMS 493 treatment exhibits improved decoding performance as compared to vehicle. F(1,144) = 14.49, ***P = 2.08 × 10−4; two-tailed F test.